| INTRODUCTION
Vedolizumab is a fully humanised monoclonal antibody that specifically inhibits a4b7 integrin binding with the mucosal addressin cell adhesion molecule-1 (MAdCAM-1).
1 By blocking a4b7 integrin, vedolizumab prevents the translocation of leucocytes, especially memory gut-homing T lymphocytes from the blood into inflamed intestinal tissue. 2 Based on the results of three pivotal phase three clinical trials, vedolizumab has been approved for the treatment of inflammatory bowel disease (IBD), including both ulcerative colitis (UC) and Crohn's disease (CD). [3] [4] [5] In June 2014, the French regulatory agency Agence Nationale de S ecurit e du Medicaments et des produits de sant e (ANSM) approved a nominative compassionate early-access programme that provided access to vedolizumab for IBD patients before marketing authorisation was granted. 6 To enter this authorisation temporaire d'utilisation (ATU) programme, physicians were required to apply on a named patient basis, allowing us to build a prospective cohort study. The
French observatory on efficacy and of vedolizumab in patients with inflammatory bowel disease (OBSERV-IBD) study, therefore, included all consecutive IBD patients who benefitted from this early-access programme. Here, we report the effectiveness and safety of vedolizumab maintenance therapy (at week 54) in patients with moderate-to-severe active UC and CD who failed anti-TNF therapy.
| PATIENTS AND METHODS

| Study population
The OBSERV-IBD cohort is a national multicentre prospective cohort study conducted in 41 French centres. From June to December 2014, patients who were treated with vedolizumab were included and followed from the first infusion at week 0 through week 54 given that they met the following conditions:
active UC (partial Mayo score >4) and CD (Harvey-Bradshaw Index ≥6) and inadequate response to, lost response to, or intolerance to either conventional therapy or at least one anti-TNF agent. 7 Each patient received written information concerning the product. Physicians were required by the ANSM to collect efficacy and safety information on a prospective basis independently from any commercial entity. The exclusion criteria included unclassified colitis, extraintestinal manifestation without significant IBD activity as the initial indication for vedolizumab, prevention of post-operative CD recurrence, ostomy, and pregnancy or lactation.
The protocol was approved by an ethics committee (CCTIRS N°1
5.403). The patient demographic and clinical characteristics at week 0 (Table S1) , as well as the efficacy and safety results at week 6 and 14, have been published elsewhere. 8 This article presents the efficacy and safety results after week 14 up to week 54.
| Vedolizumab induction therapy
Vedolizumab induction therapy consisted of three intravenous infusions of 300 mg at week 0, 2 and 6. Thereafter, vedolizumab maintenance therapy consisted of an intravenous infusion of 300 mg every 8 weeks through week 54. [3] [4] [5] The concomitant administration of steroids and/or immunomodulators, including azathioprine (≥2 mg/kg/d), mercaptopurine (≥ 1.5 mg/kg/d) or subcutaneous or intramuscular methotrexate (25 mg weekly), was performed at the investigator's discretion. No recommended tapering schedule or stopping rules were defined. The optimisation of vedolizumab therapy at a dose of 300 mg every 4 weeks through week 54 in patients who did not have a sufficient response to vedolizumab therapy was also at the investigator's discretion.
| Follow-up
All of the patients were submitted to a standardised follow-up protocol, consisting of a physical examination; calculation of HBI or partial Mayo clinic score for CD and UC patients, respectively;
CRP (mg/L), haemoglobin (g/dL), leucocyte (/10 9 /L) and platelet (/10 9 /L) counts; and data collection on adverse events. 9, 10 The evaluations were performed at week 14, 22, 30 and 54.
Endoscopic evaluations were suggested between week 30 and 54 but were not mandatory.
| Outcome measures
The primary outcome measure was a steroid-free clinical remission at week 54. Clinical remission was defined as HBI ≤4 for CD patients and a partial Mayo Clinic score <3 with a combined stool frequency and rectal bleeding subscore of ≤1. 7 The partial Mayo Clinic score consisted of the Mayo Clinic score minus the endoscopic subscore and ranged from 0 to 9. The secondary outcomes were steroid-free clinical remission at week 22 and 30; clinical remission; clinical response; steroid-free clinical response rates at week 22, 30 and 54;
and safety up to week 54. Clinical response was defined as a reduction in the HBI of at least three points from the baseline score at week 0 for CD patients and as a reduction in the partial Mayo Clinic score from the baseline score at week 0 of at least three points and a decrease in at least 30%, with a decrease in at least one point on the rectal bleeding subscale or an absolute rectal bleeding score of 0 or 1 from the baseline score at week 0 for UC patients. 7 Steroid-free means the absence of any dose of any oral steroid (prednisone, prednisolone and/or budesonide) and also includes rectal use of betamethasone. The Mayo Clinic endoscopic subscore and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) were both used to assess endoscopic activity for UC patients. Mucosal healing was defined either as the absence of any ulcer for CD patients and as a Mayo Clinic endoscopic subscore of 0 or 1 for UC patients. 11, 12 Safety was assessed by the physician in charge and retrospectively assessed from patient records. Severe adverse events were defined
as the occurrence of treatment interruption, hospitalisation, disability, persistent damage, colectomy or death.
| Statistical analysis
All of the included patients were evaluated from the week 14 visit through week 54. All of the analyses were performed on an intentto-treat manner. Patients that discontinued vedolizumab therapy between week 14 and week 54 were considered as nonresponders.
The data are expressed as a number (%) for qualitative data and as a (Table 2 and Figure 1 ). 8 The rates of clinical remission, clinical response and steroid-free clinical response are presented in Table 2 and Figure 1 . (45.6%) discontinued vedolizumab.
| Predictors of steroid-free remission at week 54
Predictors of steroid-free remission at week 54 were assessed separately in the CD and UC cohorts. In multivariate analysis in the CD (Table S3 ).
| Evolution of CRP and endoscopic activity
The CRP level decreased significantly at week 22, 30 and 52 in both the CD and UC groups compared with the CRP level at week 0 (Figure S2 and Table S4 ). C-reactive protein concentrations at week 22, 30 and 54 were lower in patients who achieved steroid-free clinical remission compared with those who did not in both the CD and UC groups, with the exception of the week 30 visit in the CD group (Table S5) . T Complete remission was defined as a Harvey-Bradshaw index ≤4 for patients with Crohn's disease and as a partial Mayo Clinic score <3 with a combined stool frequency and rectal bleeding subscore of ≤1 for patients with ulcerative colitis. Clinical response was defined as a reduction in the HarveyBradshaw index of at least three points from the week 0 baseline score for patients with Crohn's disease and as a reduction in the partial Mayo Clinic score of at least three points and a decrease in at least 30%, with a decrease in at least one point on the rectal bleeding subscale or an absolute rectal bleeding score of 0 or 1 from the week 0 baseline score for patients with ulcerative colitis. The proportions of patients who met the criteria for the latter end points during the present trial of maintenance therapy were analysed with the reference to the whole population included at week 0.
100% Crohn's disease n=173
Ulcerative colitis n=121 
The optimisation of vedolizumab therapy was significantly more frequent in the CD group at every time point, with the exception of the week 6 visit. After vedolizumab optimisation, five patients were able to resume the standard vedolizumab regimen of 300 mg every 8 weeks between week 30 and week 54 (Table 2 ).
| Safety
The analysis of adverse events was performed for all patients who received at least one dose of vedolizumab. Adverse events occurred in 62 (26.2%) out of 237 patients (Table 3) phase study, we showed that vedolizumab needs more time than anti-TNF agents to exert its maximum effect. In the latter study, steroid-free clinical response and remission rates at week 14 almost doubled in CD and UC patients compared with the week 6 results.
In the present study, we reported another difference between vedolizumab and anti-TNF agents, showing that the steroid-free clinical remission rates were stable from week 14 to week 54 in both CD and UC patients. Such a result was previously suggested in unpublished reports from the GEMINI-LTS registry, which showed long-term maintenance of the efficacy of vedolizumab in both CD and UC patients. 13, 14 However, it should be noted that very few patients experienced sustained steroid-free clinical remission from week 14 to week 54 (19.0% in patients with UC and 8.1% in patients with CD), suggesting that this scenario relies on subsequent vedolizumab optimisation.
Vedolizumab interacts with gut-selective trafficking leucocytes and prevents the infiltration of the gastrointestinal mucosa by circulating cells of the immune system. 15 Based on the results of the GEMINI trials, it has been speculated that vedolizumab is more effective in UC patients than in CD patients. [3] [4] [5] Indeed, gut selectivity could be a disadvantage given the transmural nature of CD and its association with a higher systemic inflammatory burden. 16 No such difference was observed in the week 0-14 induction phase OBSERV-IBD cohort or the in another study cohort. 8, 17, 18 In the present study, there was no difference in the clinical remission or response rates between CD and UC patients from week 6 to week 30, with the exception of a higher clinical response rate at week 6 in favour of CD patients. However, we found higher clinical remission and steroid-free clinical remission rates at week 54 in favour of UC patients. This figure was even more clinically significant considering that the sustained steroid-free clinical remission rates were 4-fold higher efficacy in patients with UC compared to those with CD. Furthermore, mucosal healing between week 30 and 54 was observed more frequently in UC patients compared with CD patients. Caution should be used when interpreting these results given that UC and CD populations are not entirely comparable.
IBDs are chronic and, more importantly, progressive diseases that lead to bowel damage and disabling conditions. 19 Beyond clinical symptoms, physicians need to take into account subclinical evidence of inflammation of the bowel, such as CRP levels, as markers of the systemic inflammatory burden and mucosal healing. In our previous study, there was no decrease in CRP levels at week 6 or 14 among both UC and CD patients. Furthermore, a high systemic inflammatory burden (CRP level > 20 mg/L) was associated with lower steroid-free clinical remission rate in both UC and CD patients. In this study, we showed that CRP levels decreased significantly in both CD and UC patients after week 14 and remained stable through week
54. An endoscopic evaluation between week 30 and 54 was performed in 68% of the UC patients and 47.5% of the CD patients.
Mucosal healing was observed in 54.8% of the UC patients and in 29% of the CD patients. Those results had to be interpreted carefully considering that mucosal healing was assessed in only a small proportion of the cohort, and it is likely that patients with active disease were less frequently reassessed. Further studies with longer follow-up periods are warranted to confirm and further explore these results.
The safety profile of vedolizumab was good and consistent with the results of the GEMINI trials. [3] [4] [5] Pooling the induction and maintenance phase results reveals that adverse events occurred in 41.2% of cases, including 13.3% of cases with serious adverse events and 2.5% of cases with adverse events leading to Upper respiratory tract infection (n of events) The maintenance period included any adverse event from the week-14 visit (not included) to the week 54 visit whereas the overall study period included any adverse event from the inclusion to the week-54 visit.
Patients with more than one adverse event were as separate events. Two rectal carcinoma was observed during the study period. The first one was diagnosed upon the vedolizumab week-2 infusion. The second one was diagnosed after proctocolectomy at week 22 for low-grade dysplasia found on surveillance random biopsies in a patients with UC and primary sclerosing cholangitis.
vedolizumab discontinuation. Two cases of rectal cancer occurred:
the first case was a 33-year-old male with long-standing CD and anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:579-594.
